The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Anti-angiogenic agents in ovarian cancer: past, present, and future
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 1×
“In addition to being a mutagenic cytotoxic, doxorubicin is known to exert its antitumor effects in part through interferon signaling [39].”
BackgroundCherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · cited 1×
“Recently, ESMO published the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies [25].”
MethodTrabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395
Self-citation
Cited by
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Cancer and stress: NextGen strategies
Cui, B., Peng, F., Lu, J., He, B., Su, Q., Luo, H., Deng, Z., Jiang, T., Su, K., Huang, Y., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.11.005 · Cited by 152
“In the clinic, the anti-angiogenic agents such as the USA Food and Drug Administration approved drug bevacizumab is widely used to inhibit tumor growth (Monk et al., 2016).”
Metadata
- Authors
- Monk, B. J., Minion, L. E., & Coleman, R. L.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 27
- Pages
- i33-i39
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2344322811
- Cited by
- 171
- References
- 3
- FWCI
- 17.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.